Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Commentary
  • Published:

The MACC1-SPON2 axis: a new biomarker and therapeutic target in colorectal cancer

Oncogene volume 36, pages 1474–1475 (2017)Cite this article

Subjects

Abstract

In this issue of the Journal, Schmid et al identify Spondin 2 (SPON2) as a prominent downstream signaling target of metastasis-associated in colon cancer 1 (MACC1) in colorectal cancer (CRC). It is shown that SPON2 mediates MACC1-induced CRC cell proliferation, invasion and metastasis in vitro and in vivo, while its high expression correlates with adverse disease free survival in clinical samples. Therefore, not only does this study shed further light into the complexity of colorectal carcinogenesis, but it also puts forward a potential novel prognostic biomarker to predict high-risk tumors before they metastasize. The MACC1/SPON2 axis may also have utility beyond an indicator of tumor aggressiveness and lends itself as a promising therapeutic target for colorectal and potentially other solid tumors.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Warusavitarne J, Ramanathan P, Kaufman A, Robinson BG, Schnitzler M . 5-Fluorouracil (5FU) treatment does not influence invasion and metastasis in microsatellite unstable (MSI-H) colorectal cancer. Int J Colorectal Dis 2006; 21: 625–631.

    Article  PubMed  Google Scholar 

  2. de Haas S, Delmar P, Bansal A, Moisse M, Miles DW, Leighl N et al. Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy. Angiogenesis 2014; 17: 909–920.

    Article  CAS  PubMed  Google Scholar 

  3. Gao S, Tibiche C, Zou J, Zaman N, Trifiro M, O'Connor-McCourt M et al. Identification and construction of combinatory cancer hallmark-based gene signature sets to predict recurrence and chemotherapy benefit in stage ii colorectal cancer. JAMA Oncol 2016; 2: 37–45.

    Article  PubMed  Google Scholar 

  4. Jackson SE, Chester JD . Personalised cancer medicine. Int J Cancer 2015; 137: 262–266.

    Article  CAS  PubMed  Google Scholar 

  5. Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006; 66: 3992–3995.

    Article  PubMed  Google Scholar 

  6. De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S . KRAS, BRAF, PIK3CA,and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 2011; 12: 594–603.

    Article  CAS  PubMed  Google Scholar 

  7. Stein U, Walther W, Arlt F, Schwabe H, Smith J, Fichtner I, Birchmeier W, Schlag PM . MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med 2009; 15: 59–67.

    Article  CAS  PubMed  Google Scholar 

  8. Zhen T, Dai S, Li H, Yang Y, Kang L, Shi H et al. MACC1 promotes carcinogenesis of colorectal cancer via β-catenin signaling pathway. Oncotarget 2014; 5: 3756–3769.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Zhang Y, Wang Z, Chen M, Peng L, Wang X, Ma Q et al. MicroRNA-143 Targets MACC1 to Inhibit Cell Invasion and Migration in Colorectal cancer. Mol Cancer. 2012; 11: 11–23.

    Article  CAS  Google Scholar 

  10. Ilm K, Kemmner W, Osterland M, Burock S, Koch G, Herrmann P et al. High MACC1 expression in combination with mutated KRAS G13 indicates poor survival of colorectal cancer patients. Mol Cancer. 2015; 14: 38.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Zhang Q, Wang X-Q, Wang J, Cui SJ, Lou XM, Yan B et al. Upregulation of spondin-2 predicts poor survival of colorectal carcinoma patients. Oncotarget 2015; 6: 15095–15110.

    PubMed  PubMed Central  Google Scholar 

  12. Lin L, Huang H, Liao W, Ma H, Liu J, Wang L et al. MACC1 supports human gastric cancer growth under metabolic stress by enhancing the Warburg effect. Oncogene 2015; 34: 2700–2710.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, St. Mark’s Hospital and Imperial College, London, UK

    P Chandrasinghe & J Warusavitarne

  2. Imperial College, Hammersmith Hospital, London, UK

    J Stebbing

Authors
  1. P Chandrasinghe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J Stebbing
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J Warusavitarne
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J Stebbing.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chandrasinghe, P., Stebbing, J. & Warusavitarne, J. The MACC1-SPON2 axis: a new biomarker and therapeutic target in colorectal cancer. Oncogene 36, 1474–1475 (2017). https://doi.org/10.1038/onc.2016.322

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2016.322

Search

Advanced search

Quick links